Research for ‘New weight-loss drug without muscle loss’ is increasingly focused on reducing body fat while preserving muscle.
Losing weight is not always the same as losing body fat.
Some people taking modern weight-loss medicines can lose lean mass along with fat. That has increased interest in treatments that could target body fat while doing more to preserve muscle.
Now, researchers at the University of California, Berkeley, have reported an interesting new approach.
In a study published in Science Advances on August 21, 2026, researchers tested an experimental compound called 5-tetradecyloxy-2-furoic acid, or TOFA.
In obese mice, TOFA increased energy use, reduced body fat and improved several measures of metabolic health. Importantly, the mice did not show a significant loss of lean muscle mass.
But there is an important point for anyone searching for a new weight-loss drug in 2026: TOFA is still experimental and has not been shown to work safely in humans.
For a broader look at the rapidly developing obesity-drug pipeline, see our guide to new weight-loss drugs in 2026.
Why Muscle Loss Matters During Weight Loss
The goal of obesity treatment is not simply to make the number on the scale smaller.
Ideally, weight loss should reduce excess body fat while preserving as much healthy lean tissue and physical function as possible.
This has become an important issue as GLP-1-based medicines have transformed obesity treatment.
Current medicines can produce substantial weight loss, but researchers are increasingly studying how to improve body composition during treatment. A 2026 expert review in JACC: Advances notes growing interest in strategies that combine weight reduction with preservation of muscle and physical function.
That is why a treatment capable of increasing fat burning without significant muscle loss could attract considerable interest.
Our earlier report on weight loss and muscle preservation explains why the type of weight lost matters.
What Is TOFA?
TOFA stands for 5-tetradecyloxy-2-furoic acid.
Unlike GLP-1 medicines, which primarily help reduce food intake and appetite, the Berkeley approach focuses on another side of the body’s energy balance.
The researchers wanted to increase the amount of energy the body uses.
Their experiments found that TOFA can affect lipid production while also activating processes involved in fat use and energy production. The research describes TOFA as an orally available small molecule that affects both lipid metabolism and energy expenditure.
This makes the approach different from simply making a person feel less hungry.
How Could TOFA Help Burn More Fat?
The researchers found that TOFA affects two important metabolic pathways.
First, it inhibits acetyl-CoA carboxylases 1 and 2, enzymes involved in lipid production.
Second, the compound acts on PPAR-alpha and PPAR-delta, pathways associated with lipid metabolism and energy use.
Together, these actions appear to shift metabolism toward greater energy expenditure and fat utilization.
In the mouse experiments, this was associated with reductions in body fat and improvements in several metabolic measures.
What Happened to Obese Mice Given TOFA?
The findings were encouraging but remain preclinical.
Obese mice treated with TOFA lost body fat without a significant reduction in lean muscle mass.
The researchers also reported improvements in:
- insulin sensitivity
- glucose control
- triglyceride levels
- fatty liver-related measures
- overall metabolic health
The treatment also increased energy expenditure.
This is different from the basic idea of simply reducing food intake. The Berkeley researchers describe the approach as increasing the body’s energy use rather than relying mainly on appetite suppression.
Could TOFA Work With GLP-1 Weight-Loss Drugs?
One of the most interesting findings was what happened when researchers combined TOFA with GLP-1-related treatments.
In mice, combining TOFA with semaglutide or tirzepatide produced greater improvements in body weight and several metabolic measures than either approach alone.
The researchers therefore view TOFA as potentially complementary to appetite-suppressing medicines rather than necessarily a replacement for them.
This could become an important area of future research.
For readers following the rapidly changing obesity-drug field, our guide to new weight-loss drugs in 2026 provides a broader look at the treatments and candidates currently being studied.
How Is This Different From Today’s GLP-1 Drugs?
Today’s leading obesity medicines work largely by changing appetite, food intake and metabolic signaling.
For example, the FDA approved Wegovy HD, a higher-dose semaglutide injection, in March 2026 for weight loss and long-term weight maintenance in eligible adults.
Tirzepatide-based treatment has also become an important part of obesity care.
The TOFA approach is different because it attempts to increase energy expenditure and alter lipid metabolism directly.
That does not mean TOFA is better than existing medicines.
It means researchers are exploring a different biological pathway.
The current obesity-treatment landscape is also changing, including the introduction of higher-dose Wegovy for weight loss.
Is TOFA Available as a Weight-Loss Drug?
No.
TOFA is not an FDA-approved weight-loss medicine.
The current research has been conducted in animals, and its safety and effectiveness in humans have not yet been established. The researchers themselves caution that human testing is still needed.
Therefore, people should not treat TOFA as an available alternative to Wegovy, Zepbound or other approved obesity medicines.
There is also no established human dose for weight loss.
What Happens Next With TOFA?
The next major question is whether TOFA can safely move from animal research into human clinical trials.
The Berkeley researchers have helped establish ReRx Therapeutics to support further development of the technology. However, moving from promising mouse findings to an approved medicine requires several stages of testing.
Researchers will need to determine:
- whether TOFA is safe in humans
- what dose is appropriate
- whether it produces meaningful fat loss in people
- whether muscle preservation occurs in humans
- whether the metabolic benefits seen in mice translate to people
- what short- and long-term side effects may occur
These questions cannot be answered by the current mouse study.
Why This Research Could Matter for Future Weight Loss
The obesity-treatment field is moving beyond the simple question of “How much weight can a drug make someone lose?”
Researchers are increasingly asking:
What type of weight is being lost?
Preserving lean mass and physical function may become increasingly important as more powerful obesity treatments are developed.
Current research is already examining muscle-sparing approaches, including drugs that target the myostatin and activin pathways.
TOFA represents another possible direction: increasing energy expenditure while changing how the body handles fat.
It is far too early to know whether this approach will eventually become an approved obesity treatment.
But the concept is scientifically important.
What Does This Mean for Americans Looking for Weight-Loss Treatment?
For people in the United States, the practical message is simple.
TOFA is not a weight-loss medicine you can currently ask your doctor to prescribe.
FDA-approved obesity medicines remain the established treatment options for eligible patients.
The FDA continues to regulate these medicines and their safety information. For example, Wegovy and Zepbound have current FDA-approved indications for appropriate adults with obesity or qualifying overweight.
Anyone considering prescription weight-loss treatment should discuss the available options with a qualified healthcare professional.
The new TOFA research is something to watch, not something to self-treat with.
The Bigger Picture: The Next Generation of Weight-Loss Drugs
TOFA is arriving at a time when obesity research is expanding rapidly.
GLP-1 medicines have already changed the treatment landscape. Newer drugs are exploring different hormone combinations, oral treatments and pathways outside traditional incretin biology.
For example, researchers are also investigating retatrutide, next-generation oral obesity medicines and treatments designed to preserve lean mass.
Our article on retatrutide for weight loss explains why this triple-hormone approach has attracted so much attention.
Readers interested in the wider pipeline can also explore our coverage of emerging obesity medicines.
The TOFA research adds another piece to that larger picture.
The future of obesity treatment may not depend on one drug or one mechanism.
Instead, researchers may eventually combine appetite control, increased energy expenditure, improved metabolic health and better preservation of lean mass.
Frequently Asked Questions
Is TOFA a new weight-loss drug?
TOFA is an experimental compound being studied as a potential treatment for obesity and related metabolic problems. It is not currently an FDA-approved weight-loss drug.
Does TOFA cause weight loss without muscle loss?
In the Berkeley study, obese mice treated with TOFA lost body fat without a significant reduction in lean muscle mass. Whether the same result occurs in humans is unknown.
Has TOFA been tested in humans?
Not yet. The reported research is preclinical animal research. Human safety and effectiveness still need to be established.
Can I buy TOFA for weight loss?
TOFA should not be considered an approved weight-loss treatment. Consumers should be especially cautious about products marketed online as research compounds or weight-loss treatments without FDA approval.
Could TOFA replace GLP-1 drugs?
There is currently no evidence that TOFA can replace GLP-1 medicines. In the mouse experiments, TOFA actually showed promising results when combined with semaglutide or tirzepatide. Human studies are needed before any clinical conclusions can be made.
Why are scientists interested in new weight loss drug without muscle loss?
Losing excess fat while preserving lean tissue could potentially improve the quality of weight loss and help protect physical function. This is one reason muscle-sparing obesity treatments are receiving increasing research attention.
Bottom Line
The new TOFA research is one of the more interesting developments in obesity research in August 2026.
In obese mice, the experimental compound increased energy expenditure, reduced body fat and improved several metabolic measures without significant muscle loss.
It also showed promising effects when combined with semaglutide or tirzepatide.
But there is a major limitation.
TOFA has not yet been proven safe or effective in humans.
For now, it should be viewed as an intriguing experimental approach rather than a new treatment available to patients.
The bigger development may be the direction obesity research is taking: scientists are looking for ways to reduce excess body fat while preserving muscle and improving long-term metabolic health.
Authoritative Sources
- University of California, Berkeley — Research announcement on TOFA and obesity
UC Berkeley research report - Science Advances — Original research paper
A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders
DOI: 10.1126/sciadv.aed3119. - JACC: Advances — Expert review on obesity pharmacotherapy and muscle preservation
JACC: Advances expert panel - U.S. Food and Drug Administration — Wegovy HD approval
FDA Wegovy HD announcement - U.S. Food and Drug Administration — Current GLP-1 regulatory information
FDA GLP-1 information